



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/518,689	12/17/2004	Antonio Guarna	50294/014001	5376
21559	7590	03/31/2006	EXAMINER CAPPS, KEVIN J	
CLARK & ELBING LLP 101 FEDERAL STREET BOSTON, MA 02110			ART UNIT 1617	
DATE MAILED: 03/31/2006				

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary	Application No. 10/518,689	Applicant(s) GUARNA ET AL.	
	Examiner Kevin J. Capps	Art Unit 1617	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 22-42 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☐ Claim(s) ____ is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☒ Claim(s) 22-42 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. ____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____. |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date ____. | 6) <input type="checkbox"/> Other: ____. |

DETAILED ACTION

Status of the Claims

1. In a preliminary amendment filed on December 17, 2004, claims 1-21 were cancelled and new claims 22-42 were added. Claims 22-42 are the subject of the following restriction requirement.

Election/Restrictions

2. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 22-26, 41, and 42 (in part), drawn to compounds of formula I and pharmaceutical compositions comprising said compounds.

Group II, claim(s) 22-26, 41, and 42 (in part), drawn to compounds of formula II and pharmaceutical compositions comprising said compounds.

Group III, claim(s) 22-26, 41, and 42 (in part), drawn to compounds of formula III and pharmaceutical compositions comprising said compounds.

Group IV, claim(s) 27 and 28 (in part), drawn to a method of treating Alzheimer's disease comprising administering compositions comprising compounds of formula I.

Group V, claim(s) 27 and 28 (in part), drawn to a method of treating Alzheimer's disease comprising administering compositions comprising compounds of formula II.

Group VI, claim(s) 27 and 28 (in part), drawn to a method of treating Alzheimer's disease comprising administering compositions comprising compounds of formula III.

Art Unit: 1617

Group VII, claim(s) 27 and 28 (in part), drawn to a method of treating amyotrophic lateral sclerosis comprising administering compositions comprising compounds of formula I.

Group VIII, claim(s) 27 and 28 (in part), drawn to a method of treating amyotrophic lateral sclerosis comprising administering compositions comprising compounds of formula II.

Group IX, claim(s) 27 and 28 (in part), drawn to a method of treating amyotrophic lateral sclerosis comprising administering compositions comprising compounds of formula III.

Group X, claim(s) 27 and 28 (in part), drawn to a method of treating Huntington's disease comprising administering compositions comprising compounds of formula I.

Group XI, claim(s) 27 and 28 (in part), drawn to a method of treating Huntington's disease comprising administering compositions comprising compounds of formula II.

Group XII, claim(s) 27 and 28 (in part), drawn to a method of treating Huntington's disease comprising administering compositions comprising compounds of formula III.

Group XIII, claim(s) 27 and 28 (in part), drawn to a method of treating multiple sclerosis comprising administering compositions comprising compounds of formula I.

Group XIV, claim(s) 27 and 28 (in part), drawn to a method of treating multiple sclerosis comprising administering compositions comprising compounds of formula II.

Group XV, claim(s) 27 and 28 (in part), drawn to a method of treating multiple sclerosis comprising administering compositions comprising compounds of formula III.

Group XVI, claim(s) 27 and 28 (in part), drawn to a method of treating epilepsy comprising administering compositions comprising compounds of formula I.

Group XVII, claim(s) 27 and 28 (in part), drawn to a method of treating epilepsy comprising administering compositions comprising compounds of formula II.

Group XVIII, claim(s) 27 and 28 (in part), drawn to a method of treating epilepsy comprising administering compositions comprising compounds of formula III.

Group XIX, claim(s) 27 and 28 (in part), drawn to a method of treating Down syndrome comprising administering compositions comprising compounds of formula I.

Group XX, claim(s) 27 and 28 (in part), drawn to a method of treating Down syndrome comprising administering compositions comprising compounds of formula II.

Art Unit: 1617

Group XXI, claim(s) 27 and 28 (in part), drawn to a method of treating Down syndrome comprising administering compositions comprising compounds of formula III.

Group XXII, claim(s) 27 and 28 (in part), drawn to a method of treating nervous deafness comprising administering compositions comprising compounds of formula I.

Group XXIII, claim(s) 27 and 28 (in part), drawn to a method of treating nervous deafness comprising administering compositions comprising compounds of formula II.

Group XIV, claim(s) 27 and 28 (in part), drawn to a method of treating nervous deafness comprising administering compositions comprising compounds of formula III.

Group XV, claim(s) 27 and 28 (in part), drawn to a method of treating Ménière's disease comprising administering compositions comprising compounds of formula I.

Group XVI, claim(s) 27 and 28 (in part), drawn to a method of treating Ménière's disease comprising administering compositions comprising compounds of formula II.

Group XVII, claim(s) 27 and 28 (in part), drawn to a method of treating Ménière's disease comprising administering compositions comprising compounds of formula III.

Group XVIII, claim(s) 27 and 29 (in part), drawn to a method of treating polio comprising administering compositions comprising compounds of formula I.

Group XIX, claim(s) 27 and 29 (in part), drawn to a method of treating polio comprising administering compositions comprising compounds of formula II.

Group XX, claim(s) 27 and 29 (in part), drawn to a method of treating polio comprising administering compositions comprising compounds of formula III.

Group XXI, claim(s) 27 and 29 (in part), drawn to a method of treating HIV comprising administering compositions comprising compounds of formula I.

Group XXII, claim(s) 27 and 29 (in part), drawn to a method of treating HIV comprising administering compositions comprising compounds of formula II.

Group XXIII, claim(s) 27 and 29 (in part), drawn to a method of treating HIV comprising administering compositions comprising compounds of formula III.

Group XXIV, claim(s) 27 and 30 (in part), drawn to a method of treating Charcot-Marie-Tooth disease comprising administering compositions comprising compounds of formula I.

Art Unit: 1617

Group XXV, claim(s) 27 and 30 (in part), drawn to a method of treating Charcot-Marie-Tooth disease comprising administering compositions comprising compounds of formula II.

Group XXVI, claim(s) 27 and 30 (in part), drawn to a method of treating Charcot-Marie-Tooth disease comprising administering compositions comprising compounds of formula III.

Group XXVII, claim(s) 27 and 30 (in part), drawn to a method of treating Refsum disease comprising administering compositions comprising compounds of formula I.

Group XXVIII, claim(s) 27 and 30 (in part), drawn to a method of treating Refsum disease comprising administering compositions comprising compounds of formula II.

Group XXIX, claim(s) 27 and 30 (in part), drawn to a method of treating Refsum disease comprising administering compositions comprising compounds of formula III.

Group XXX, claim(s) 27 and 30 (in part), drawn to a method of treating abetalipoproteinemia comprising administering compositions comprising compounds of formula I.

Group XXXI, claim(s) 27 and 30 (in part), drawn to a method of treating abetalipoproteinemia comprising administering compositions comprising compounds of formula II.

Group XXXII, claim(s) 27 and 30 (in part), drawn to a method of treating abetalipoproteinemia comprising administering compositions comprising compounds of formula III.

Group XXXIII, claim(s) 27 and 30 (in part), drawn to a method of treating Tangier disease comprising administering compositions comprising compounds of formula I.

Group XXXIV, claim(s) 27 and 30 (in part), drawn to a method of treating Tangier disease comprising administering compositions comprising compounds of formula II.

Group XXXV, claim(s) 27 and 30 (in part), drawn to a method of treating Tangier disease comprising administering compositions comprising compounds of formula III.

Group XXXVI, claim(s) 27 and 30 (in part), drawn to a method of treating Krabbe disease comprising administering compositions comprising compounds of formula I.

Group XXXVII, claim(s) 27 and 30 (in part), drawn to a method of treating Krabbe disease comprising administering compositions comprising compounds of formula II.

Art Unit: 1617

Group XXXVIII, claim(s) 27 and 30 (in part), drawn to a method of treating Krabbe disease comprising administering compositions comprising compounds of formula III.

Group XXXIX, claim(s) 27 and 30 (in part), drawn to a method of treating metachromic leukodystrophy comprising administering compositions comprising compounds of formula I.

Group XL, claim(s) 27 and 30 (in part), drawn to a method of treating metachromic leukodystrophy comprising administering compositions comprising compounds of formula II.

Group XLI, claim(s) 27 and 30 (in part), drawn to a method of treating metachromic leukodystrophy comprising administering compositions comprising compounds of formula III.

Group XLII, claim(s) 27 and 30 (in part), drawn to a method of treating Fabry disease comprising administering compositions comprising compounds of formula I.

Group XLIII, claim(s) 27 and 30 (in part), drawn to a method of treating Fabry disease comprising administering compositions comprising compounds of formula II.

Group XLIV, claim(s) 27 and 30 (in part), drawn to a method of treating Fabry disease comprising administering compositions comprising compounds of formula III.

Group XLV, claim(s) 27 and 30 (in part), drawn to a method of treating Dejerine-Sottas disease comprising administering compositions comprising compounds of formula I.

Group XLVI, claim(s) 27 and 30 (in part), drawn to a method of treating Dejerine-Sottas disease comprising administering compositions comprising compounds of formula II.

Group XLVII, claim(s) 27 and 30 (in part), drawn to a method of treating Dejerine-Sottas disease comprising administering compositions comprising compounds of formula III.

Group XLVIII, claim(s) 27 and 31 (in part), drawn to a method of treating diffuse atrophy of cerebral cortex comprising administering compositions comprising compounds of formula I.

Group XLIX, claim(s) 27 and 31 (in part), drawn to a method of treating diffuse atrophy of cerebral cortex comprising administering compositions comprising compounds of formula II.

Art Unit: 1617

Group L, claim(s) 27 and 31 (in part), drawn to a method of treating diffuse atrophy of cerebral cortex comprising administering compositions comprising compounds of formula III.

Group LI, claim(s) 27 and 31 (in part), drawn to a method of treating Lewy body dementia comprising administering compositions comprising compounds of formula I.

Group LII, claim(s) 27 and 31 (in part), drawn to a method of treating Lewy body dementia comprising administering compositions comprising compounds of formula II.

Group LII, claim(s) 27 and 31 (in part), drawn to a method of treating Lewy body dementia comprising administering compositions comprising compounds of formula III.

Group LIII, claim(s) 27 and 31 (in part), drawn to a method of treating Pick's disease comprising administering compositions comprising compounds of formula I.

Group LIV, claim(s) 27 and 31 (in part), drawn to a method of treating Pick's disease comprising administering compositions comprising compounds of formula II.

Group LV, claim(s) 27 and 31 (in part), drawn to a method of treating Pick's disease comprising administering compositions comprising compounds of formula III.

Group LVI, claim(s) 27 and 31 (in part), drawn to a method of treating mesolimbocortical dementia comprising administering compositions comprising compounds of formula I.

Group LVII, claim(s) 27 and 31 (in part), drawn to a method of treating mesolimbocortical dementia comprising administering compositions comprising compounds of formula II.

Group LVIII, claim(s) 27 and 31 (in part), drawn to a method of treating mesolimbocortical dementia comprising administering compositions comprising compounds of formula III.

Group LIX, claim(s) 27 and 31 (in part), drawn to a method of treating neuronal ceroid lipofuscinosis comprising administering compositions comprising compounds of formula I.

Group LX, claim(s) 27 and 31 (in part), drawn to a method of treating neuronal ceroid lipofuscinosis comprising administering compositions comprising compounds of formula II.

Art Unit: 1617

Group LXI, claim(s) 27 and 31 (in part), drawn to a method of treating neuronal ceroid lipofuscinosis comprising administering compositions comprising compounds of formula III.

Group LXII, claim(s) 27 and 31 (in part), drawn to a method of treating thalamic degeneration comprising administering compositions comprising compounds of formula I.

Group LXIII, claim(s) 27 and 31 (in part), drawn to a method of treating thalamic degeneration comprising administering compositions comprising compounds of formula II.

Group LXIV, claim(s) 27 and 31 (in part), drawn to a method of treating thalamic degeneration comprising administering compositions comprising compounds of formula III.

Group LXV, claim(s) 27 and 31 (in part), drawn to a method of treating cortico-striatal degeneration comprising administering compositions comprising compounds of formula I.

Group LXVI, claim(s) 27 and 31 (in part), drawn to a method of treating cortico-striatal degeneration comprising administering compositions comprising compounds of formula II.

Group LXVII, claim(s) 27 and 31 (in part), drawn to a method of treating cortico-striatal degeneration comprising administering compositions comprising compounds of formula III.

Group LXVIII, claim(s) 27 and 31 (in part), drawn to a method of treating cerebro-cerebellar degeneration comprising administering compositions comprising compounds of formula I.

Group LXIX, claim(s) 27 and 31 (in part), drawn to a method of treating cerebro-cerebellar degeneration comprising administering compositions comprising compounds of formula II.

Group LXX, claim(s) 27 and 31 (in part), drawn to a method of treating cerebro-cerebellar degeneration comprising administering compositions comprising compounds of formula III.

Group LXXI, claim(s) 27 and 31 (in part), drawn to a method of treating mesolimbocortical dementia comprising administering compositions comprising compounds of formula I.

Art Unit: 1617

Group LXXII, claim(s) 27 and 31 (in part), drawn to a method of treating mesolimbocortical dementia comprising administering compositions comprising compounds of formula II.

Group LXXIII, claim(s) 27 and 31 (in part), drawn to a method of treating mesolimbocortical dementia comprising administering compositions comprising compounds of formula III.

Group LXXIV, claim(s) 27 and 31 (in part), drawn to a method of treating familial dementia with spastic paraparesis comprising administering compositions comprising compounds of formula I.

Group LXXV, claim(s) 27 and 31 (in part), drawn to a method of treating familial dementia with spastic paraparesis comprising administering compositions comprising compounds of formula II.

Group LXXVI, claim(s) 27 and 31 (in part), drawn to a method of treating familial dementia with spastic paraparesis comprising administering compositions comprising compounds of formula III.

Group LXXVII, claim(s) 27 and 31 (in part), drawn to a method of treating polyglucosan bodies disease comprising administering compositions comprising compounds of formula I.

Group LXXVIII, claim(s) 27 and 31 (in part), drawn to a method of treating polyglucosan bodies disease comprising administering compositions comprising compounds of formula II.

Group LXXIX, claim(s) 27 and 31 (in part), drawn to a method of treating polyglucosan bodies disease comprising administering compositions comprising compounds of formula III.

Group LXXX, claim(s) 27 and 31 (in part), drawn to a method of treating Shy-Drager syndrome comprising administering compositions comprising compounds of formula I.

Group LXXXI, claim(s) 27 and 31 (in part), drawn to a method of treating Shy-Drager syndrome comprising administering compositions comprising compounds of formula II.

Group LXXXII, claim(s) 27 and 31 (in part), drawn to a method of treating Shy-Drager syndrome comprising administering compositions comprising compounds of formula III.

Art Unit: 1617

Group LXXXIII, claim(s) 27 and 31 (in part), drawn to a method of treating olivopontocerebellar atrophy comprising administering compositions comprising compounds of formula I.

Group LXXXIV, claim(s) 27 and 31 (in part), drawn to drawn to a method of treating olivopontocerebellar atrophy comprising administering compositions comprising compounds of formula II.

Group LXXXV, claim(s) 27 and 31 (in part), drawn to drawn to a method of treating olivopontocerebellar atrophy comprising administering compositions comprising compounds of formula III.

Group LXXXVI, claim(s) 27 and 31 (in part), drawn to a method of treating progressive supranuclear palsy comprising administering compositions comprising compounds of formula I.

Group LXXXVII, claim(s) 27 and 31 (in part), drawn to drawn to a method of treating progressive supranuclear palsy comprising administering compositions comprising compounds of formula II.

Group LXXXVIII, claim(s) 27 and 31 (in part), drawn to drawn to a method of treating progressive supranuclear palsy comprising administering compositions comprising compounds of formula III.

Group LXXXIX, claim(s) 27 and 31 (in part), drawn to a method of treating deforming muscular dystony comprising administering compositions comprising compounds of formula I.

Group XC, claim(s) 27 and 31 (in part), drawn to drawn to a method of treating deforming muscular dystony comprising administering compositions comprising compounds of formula II.

Group XCI, claim(s) 27 and 31 (in part), drawn to drawn to a method of treating deforming muscular dystony comprising administering compositions comprising compounds of formula III.

Group XCII, claim(s) 27 and 31 (in part), drawn to a method of treating Hallervorden-Spatz disease comprising administering compositions comprising compounds of formula I.

Group XCIII, claim(s) 27 and 31 (in part), drawn to drawn to a method of treating Hallervorden-Spatz disease comprising administering compositions comprising compounds of formula II.

Art Unit: 1617

Group XCIV, claim(s) 27 and 31 (in part), drawn to a method of treating Hallervorden-Spatz disease comprising administering compositions comprising compounds of formula III.

Group XCV, claim(s) 27 and 31 (in part), drawn to a method of treating Meige's syndrome comprising administering compositions comprising compounds of formula I.

Group XCVI, claim(s) 27 and 31 (in part), drawn to a method of treating Meige's syndrome comprising administering compositions comprising compounds of formula II.

Group XCVII, claim(s) 27 and 31 (in part), drawn to a method of treating Meige's syndrome comprising administering compositions comprising compounds of formula III.

Group XCVIII, claim(s) 27 and 31 (in part), drawn to a method of treating familial shivering comprising administering compositions comprising compounds of formula I.

Group XCIX, claim(s) 27 and 31 (in part), drawn to a method of treating familial shivering comprising administering compositions comprising compounds of formula II.

Group C, claim(s) 27 and 31 (in part), drawn to a method of treating familial shivering comprising administering compositions comprising compounds of formula III.

Group CI, claim(s) 27 and 31 (in part), drawn to a method of treating Gilles de la Tourette syndrome comprising administering compositions comprising compounds of formula I.

Group CII, claim(s) 27 and 31 (in part), drawn to a method of treating Gilles de la Tourette syndrome comprising administering compositions comprising compounds of formula II.

Group CIII, claim(s) 27 and 31 (in part), drawn to a method of treating Gilles de la Tourette syndrome comprising administering compositions comprising compounds of formula III.

Group CIV, claim(s) 27 and 31 (in part), drawn to a method of treating chorea-acanthocytosis syndrome comprising administering compositions comprising compounds of formula I.

Group CV, claim(s) 27 and 31 (in part), drawn to a method of treating chorea-acanthocytosis syndrome comprising administering compositions comprising compounds of formula II.

Art Unit: 1617

Group CVI, claim(s) 27 and 31 (in part), drawn to drawn to a method of treating chorea-acanthocytosis syndrome comprising administering compositions comprising compounds of formula III.

Group CVII, claim(s) 27 and 31 (in part), drawn to a method of treating Friedreich's ataxia comprising administering compositions comprising compounds of formula I.

Group CVIII, claim(s) 27 and 31 (in part), drawn to drawn to a method of treating Friedreich's ataxia comprising administering compositions comprising compounds of formula II.

Group CIX, claim(s) 27 and 31 (in part), drawn to drawn to a method of treating Friedreich's ataxia comprising administering compositions comprising compounds of formula III.

Group CX, claim(s) 27 and 31 (in part), drawn to a method of treating Holmes' corticocerebellar familial atrophy comprising administering compositions comprising compounds of formula I.

Group CXI, claim(s) 27 and 31 (in part), drawn to drawn to a method of treating Holmes' corticocerebellar familial atrophy comprising administering compositions comprising compounds of formula II.

Group CXII, claim(s) 27 and 31 (in part), drawn to drawn to a method of treating Holmes' corticocerebellar familial atrophy comprising administering compositions comprising compounds of formula III.

Group CXIII, claim(s) 27 and 31 (in part), drawn to a method of treating Gerstmann-Straussler-Scheinker disease comprising administering compositions comprising compounds of formula I.

Group CXIV, claim(s) 27 and 31 (in part), drawn to drawn to a method of treating Gerstmann-Straussler-Scheinker disease comprising administering compositions comprising compounds of formula II.

Group CXV, claim(s) 27 and 31 (in part), drawn to drawn to a method of treating Gerstmann-Straussler-Scheinker disease comprising administering compositions comprising compounds of formula III.

Group CXVI, claim(s) 27 and 31 (in part), drawn to a method of treating progressive spinal muscular atrophy comprising administering compositions comprising compounds of formula I.

Art Unit: 1617

Group CXVII, claim(s) 27 and 31 (in part), drawn to a method of treating progressive spinal muscular atrophy comprising administering compositions comprising compounds of formula II.

Group CXVIII, claim(s) 27 and 31 (in part), drawn to a method of treating progressive spinal muscular atrophy comprising administering compositions comprising compounds of formula III.

Group CXIX, claim(s) 27 and 31 (in part), drawn to a method of treating spastic paraplegia comprising administering compositions comprising compounds of formula I.

Group CXX, claim(s) 27 and 31 (in part), drawn to a method of treating spastic paraplegia comprising administering compositions comprising compounds of formula II.

Group CXXI, claim(s) 27 and 31 (in part), drawn to a method of treating spastic paraplegia comprising administering compositions comprising compounds of formula III.

Group CXXII, claim(s) 27 and 31 (in part), drawn to a method of treating peroneal muscular atrophy comprising administering compositions comprising compounds of formula I.

Group CXXIII, claim(s) 27 and 31 (in part), drawn to a method of treating peroneal muscular atrophy comprising administering compositions comprising compounds of formula II.

Group CXXIV, claim(s) 27 and 31 (in part), drawn to a method of treating peroneal muscular atrophy comprising administering compositions comprising compounds of formula III.

Group CXXV, claim(s) 27 and 31 (in part), drawn to a method of treating hypertrophic interstitial polyneuropathy comprising administering compositions comprising compounds of formula I.

Group CXXVI, claim(s) 27 and 31 (in part), drawn to a method of treating hypertrophic interstitial polyneuropathy comprising administering compositions comprising compounds of formula II.

Group CXXVII, claim(s) 27 and 31 (in part), drawn to a method of treating hypertrophic interstitial polyneuropathy comprising administering compositions comprising compounds of formula III.

Group CXXVIII, claim(s) 27 and 31 (in part), drawn to a method of treating polyneuritic ataxic hereditary ataxia comprising administering compositions comprising compounds of formula I.

Art Unit: 1617

Group CXXIX, claim(s) 27 and 31 (in part), drawn to drawn to a method of treating polyneuritic ataxic hereditary comprising administering compositions comprising compounds of formula II.

Group CXXX, claim(s) 27 and 31 (in part), drawn to drawn to a method of treating polyneuritic ataxic hereditary comprising administering compositions comprising compounds of formula III.

Group CXXXI, claim(s) 27 and 32 (in part), drawn to a method of treating optic nerve neuropathies comprising administering compositions comprising compounds of formula I.

Group CXXXII, claim(s) 27 and 32 (in part), drawn to drawn to a method of treating optic nerve neuropathies comprising administering compositions comprising compounds of formula II.

Group CXXXIII, claim(s) 27 and 32 (in part), drawn to drawn to a method of treating optic nerve neuropathies comprising administering compositions comprising compounds of formula III.

Group CXXXIV, claim(s) 27 and 32 (in part), drawn to a method of treating retinal degeneration comprising administering compositions comprising compounds of formula I.

Group CXXXV, claim(s) 27 and 32 (in part), drawn to drawn to a method of treating retinal degeneration comprising administering compositions comprising compounds of formula II.

Group CXXXVI, claim(s) 27 and 32 (in part), drawn to drawn to a method of treating retinal degeneration comprising administering compositions comprising compounds of formula III.

Group CXXXVII, claim(s) 27 and 32 (in part), drawn to a method of treating ophthalmoplegia comprising administering compositions comprising compounds of formula I.

Group CXXXVIII, claim(s) 27 and 32 (in part), drawn to drawn to a method of treating ophthalmoplegia comprising administering compositions comprising compounds of formula II.

Group CXXXIX, claim(s) 27 and 32 (in part), drawn to drawn to a method of treating ophthalmoplegia comprising administering compositions comprising compounds of formula III.

Art Unit: 1617

Group CXL, claim(s) 27 and 32 (in part), drawn to a method of treating glaucoma comprising administering compositions comprising compounds of formula I.

Group CXLI, claim(s) 27 and 32 (in part), drawn to drawn to a method of treating glaucoma comprising administering compositions comprising compounds of formula II.

Group CXLII, claim(s) 27 and 32 (in part), drawn to drawn to a method of treating glaucoma comprising administering compositions comprising compounds of formula III.

Group CXLIII, claim(s) 27 and 32 (in part), drawn to a method of treating neurotrophic ulcers comprising administering compositions comprising compounds of formula I.

Group CXLIV, claim(s) 27 and 32 (in part), drawn to drawn to a method of treating neurotrophic ulcers comprising administering compositions comprising compounds of formula II.

Group CXLV, claim(s) 27 and 32 (in part), drawn to drawn to a method of treating neurotrophic ulcers comprising administering compositions comprising compounds of formula III.

Group CXLVI, claim(s) 27 and 32 (in part), drawn to a method of treating post-traumatic and post-infective corneal disorders comprising administering compositions comprising compounds of formula I.

Group CXLVII, claim(s) 27 and 32 (in part), drawn to drawn to a method of treating post-traumatic and post-infective corneal disorders comprising administering compositions comprising compounds of formula II.

Group CXLVIII, claim(s) 27 and 32 (in part), drawn to drawn to a method of treating post-traumatic and post-infective corneal disorders comprising administering compositions comprising compounds of formula III.

Group CXLIX, claim(s) 27 and 33 (in part), drawn to a method of treating interstitial cystitis comprising administering compositions comprising compounds of formula I.

Group CL, claim(s) 27 and 33 (in part), drawn to drawn to a method of treating interstitial cystitis comprising administering compositions comprising compounds of formula II.

Group CLI, claim(s) 27 and 33 (in part), drawn to drawn to a method of treating interstitial cystitis comprising administering compositions comprising compounds of formula III.

Art Unit: 1617

Group CLII, claim(s) 27 and 33 (in part), drawn to a method of treating diabetic cystitis comprising administering compositions comprising compounds of formula I.

Group CLIII, claim(s) 27 and 33 (in part), drawn to drawn to a method of treating diabetic cystitis comprising administering compositions comprising compounds of formula II.

Group CLIV, claim(s) 27 and 33 (in part), drawn to drawn to a method of treating diabetic cystitis comprising administering compositions comprising compounds of formula III.

Group CLV, claim(s) 27 and 34 (in part), drawn to a method of treating myocardial infarction comprising administering compositions comprising compounds of formula I.

Group CLVI, claim(s) 27 and 34 (in part), drawn to drawn to a method of treating myocardial infarction comprising administering compositions comprising compounds of formula II.

Group CLVII, claim(s) 27 and 34 (in part), drawn to drawn to a method of treating myocardial infarction comprising administering compositions comprising compounds of formula III.

Group CLVIII, claim(s) 27 and 34 (in part), drawn to a method of treating stroke comprising administering compositions comprising compounds of formula I.

Group CLIX, claim(s) 27 and 34 (in part), drawn to drawn to a method of treating stroke comprising administering compositions comprising compounds of formula II.

Group CLX, claim(s) 27 and 34 (in part), drawn to drawn to a method of treating stroke comprising administering compositions comprising compounds of formula III.

Group CLXI, claim(s) 27 and 34 (in part), drawn to a method of treating cerebral aneurysms comprising administering compositions comprising compounds of formula I.

Group CLXII, claim(s) 27 and 34 (in part), drawn to drawn to a method of treating cerebral aneurysms comprising administering compositions comprising compounds of formula II.

Group CLXIII, claim(s) 27 and 34 (in part), drawn to drawn to a method of treating cerebral aneurysms comprising administering compositions comprising compounds of formula III.

Art Unit: 1617

Group CLXIV, claim(s) 27 and 34 (in part), drawn to a method of treating gastro-duodenal ulcers comprising administering compositions comprising compounds of formula I.

Group CLXV, claim(s) 27 and 34 (in part), drawn to drawn to a method of treating gastro-duodenal ulcers comprising administering compositions comprising compounds of formula II.

Group CLXVI, claim(s) 27 and 34 (in part), drawn to drawn to a method of treating gastro-duodenal ulcers comprising administering compositions comprising compounds of formula III.

Group CLXV, claim(s) 27 and 34 (in part), drawn to a method of treating wound healing comprising administering compositions comprising compounds of formula I.

Group CLXVI, claim(s) 27 and 34 (in part), drawn to drawn to a method of treating wound healing comprising administering compositions comprising compounds of formula II.

Group CLXVII, claim(s) 27 and 34 (in part), drawn to drawn to a method of treating wound healing comprising administering compositions comprising compounds of formula III.

Group CLXVIII, claim(s) 27 and 34 (in part), drawn to a method of treating peripheral vasculopathies comprising administering compositions comprising compounds of formula I.

Group CLXIX, claim(s) 27 and 34 (in part), drawn to drawn to a method of treating peripheral vasculopathies comprising administering compositions comprising compounds of formula II.

Group CLXX, claim(s) 27 and 34 (in part), drawn to drawn to a method of treating peripheral vasculopathies comprising administering compositions comprising compounds of formula III.

Group CLXXI, claim(s) 27 (in part) and 35, drawn to a method of treating acquired immunodeficiency disease comprising administering compositions comprising compounds of formula I.

Group CLXXII, claim(s) 27 (in part) and 35, drawn to a method of treating acquired immunodeficiency disease comprising administering compositions comprising compounds of formula II.

Art Unit: 1617

Group CLXXIII, claim(s) 27 (in part) and 35, drawn to a method of treating acquired immunodeficiency disease comprising administering compositions comprising compounds of formula III.

Group CLXXIV, claim(s) 36 and 37, drawn to a method of promoting growth and/or survival of neuronal cells using compounds of formula I.

Group CLXXV, claim(s) 36 and 37, drawn to a method of promoting growth and/or survival of neuronal cells using compounds of formula II.

Group CLXXVI, claim(s) 36 and 37, drawn to a method of promoting growth and/or survival of neuronal cells using compounds of formula III.

Group CLXXVII, claim(s) 38 (in part), drawn to a method of making a culture and storage media comprising compounds of formula I.

Group CLXXVIII, claim(s) 38 (in part), drawn to a method of making a culture and storage media comprising compounds of formula II.

Group CLXXIX, claim(s) 38 (in part), drawn to a method of making a culture and storage media comprising compounds of formula III.

Group CLXXX, claim(s) 39 and 40 (in part), drawn to a method of imaging tissues and organs containing neurotrophine receptors using labeled compounds of formula I.

Group CLXXXI, claim(s) 39 and 40 (in part), drawn to a method of imaging tissues and organs containing neurotrophine receptors using labeled compounds of formula II.

Group CLXXXIII, claim(s) 39 and 40 (in part), drawn to a method of imaging tissues and organs containing neurotrophine receptors using labeled compounds of formula III.

3. The inventions listed as Groups I-CLXXXIII do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The corresponding technical feature of the instant application is the 3-aza-bicyclo[3.2.1]octane core structural element of the compounds of formulae I, II, and III. The 3-aza-bicyclo[3.2.1]octane core structural element of the compounds of formulae I, II, and III, as well as the compounds of formulae I and II, have been described in the literature (see Applicant-cited references on IDS: Guarna, A., et al. *J. Org. Chem.* **1999**, *64*, 7347-7364, and, Machetti, F., et al. *Org. Lett.* **2000**, *2*, 3987-3990.). Thus, no special technical feature exists that defines a contribution which each of the inventions, considered as a whole, makes over the prior art.

4. Because the restriction/election requirement is complex, a telephone call to applicant's agent to request an oral election was not made. See MPEP § 812.01.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.


5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kevin J. Capps whose telephone number is (571) 272-8646. The examiner can normally be reached on Monday-Friday, 8:30am-5pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

KC



SAN-MING HUI
PRIMARY EXAMINER